Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Raymakers

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Vox Sanguinis|January 1, 1985
Concentration of hematopoietic progenitor cells from human bone marrow by a new type of blood component separatorC G Figdor, T de Witte, R Raymakers, et al.
Experimental Hematology|May 1, 1991
Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cellsN Van Der Lely, T De Witte, P Muus, et al.
Leukemia|March 13, 2001
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearanceM Smeets, R Raymakers, P Muus, et al.
Annals of Hematology|May 1, 1994
In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicityN Van der Lely, T De Witte, J Wessels, et al.
British Journal of Haematology|May 1, 1991
In vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute nonlymphocytic leukaemiaR Raymakers, T De Witte, J Joziasse, et al.
The Netherlands Journal of Medicine|September 24, 2008
Defective interferon-gamma production in patients with hairy cell leukaemiaM G Netea, O Hoitink, B J Kullberg, et al.
British Journal of Haematology|June 1, 1996
CD34 selections from myeloma peripheral blood cell autografts contain residual tumour cells due to impurity, not to CD34+ myeloma cellsP Willems, A Croockewit, R Raymakers, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 27, 2005
[Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]H Lokhorst, P C Huijgens, R Raymakers, et al.
Bone Marrow Transplantation|July 11, 2017
In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic reviewR Oostvogels, S M Uniken Venema, M de Witte, et al.
British Journal of Haematology|February 1, 1997
A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicityM Smeets, R Raymakers, G Vierwinden, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Vox Sanguinis|January 1, 1985
Concentration of hematopoietic progenitor cells from human bone marrow by a new type of blood component separatorC G Figdor, T de Witte, R Raymakers, et al.
Experimental Hematology|May 1, 1991
Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cellsN Van Der Lely, T De Witte, P Muus, et al.
Leukemia|March 13, 2001
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearanceM Smeets, R Raymakers, P Muus, et al.
Annals of Hematology|May 1, 1994
In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicityN Van der Lely, T De Witte, J Wessels, et al.
British Journal of Haematology|May 1, 1991
In vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute nonlymphocytic leukaemiaR Raymakers, T De Witte, J Joziasse, et al.
The Netherlands Journal of Medicine|September 24, 2008
Defective interferon-gamma production in patients with hairy cell leukaemiaM G Netea, O Hoitink, B J Kullberg, et al.
British Journal of Haematology|June 1, 1996
CD34 selections from myeloma peripheral blood cell autografts contain residual tumour cells due to impurity, not to CD34+ myeloma cellsP Willems, A Croockewit, R Raymakers, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 27, 2005
[Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]H Lokhorst, P C Huijgens, R Raymakers, et al.
Bone Marrow Transplantation|July 11, 2017
In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic reviewR Oostvogels, S M Uniken Venema, M de Witte, et al.
British Journal of Haematology|February 1, 1997
A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicityM Smeets, R Raymakers, G Vierwinden, et al.
Pageof 4